Yarrington v. SOLVAY PHARMACEUTICALS, INC.

697 F. Supp. 2d 1057, 2010 U.S. Dist. LEXIS 24060, 2010 WL 1006518
CourtDistrict Court, D. Minnesota
DecidedMarch 16, 2010
Docket09-CV-2261 (RHK/RLE)
StatusPublished
Cited by16 cases

This text of 697 F. Supp. 2d 1057 (Yarrington v. SOLVAY PHARMACEUTICALS, INC.) is published on Counsel Stack Legal Research, covering District Court, D. Minnesota primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Yarrington v. SOLVAY PHARMACEUTICALS, INC., 697 F. Supp. 2d 1057, 2010 U.S. Dist. LEXIS 24060, 2010 WL 1006518 (mnd 2010).

Opinion

*1059 ORDER GRANTING SETTLEMENT CLASS COUNSEL’S MOTION FOR ATTORNEYS’ FEES AND COSTS, AND PAYMENT OF SERVICE AWARDS TO THE NAMED PLAINTIFFS

RICHARD H. KYLE, District Judge.

This matter is before the Court on Settlement Class Counsel’s Motion for Attorneys’ Fees and Costs, and Payment of Service Awards to the Named Plaintiffs. For the reasons set forth below, the Motion will be granted.

I. BACKGROUND

A. Litigation Summary.

This case has been pending since March 30, 2004. It was originally brought against Solvay Pharmaceuticals, Inc. (“Solvay”) and its parent, Solvay America (collectively “Defendants”) by Plaintiff Judith Yarrington (‘Yarrington”), on behalf of herself-and all others similarly situated, who purchased and ingested Estratest and Estratest H.S. (collectively “Estratest”) hormone-replacement therapy drugs sold by Solvay after March 8, 1998. Yarrington commenced her class action in the District Court for the First Judicial District, Dakota County, Minnesota. Alleging that Defendants falsely and deceptively advertised Estratest as an “FDA-approved” drug, Yarrington asserted claims against Defendants for: (1) violations of the Consumer Fraud Act, Minn.Stat. § 325F.68, et seq.; (2) violations of the Deceptive Trade Practices Act, Minn.Stat. § 325D.43, et seq.; (3) violations of the Unlawful Trade Practices Act, Minn.Stat. § 325D.09, et seq.; (4) violations of the False Statement in Advertising Act, Minn.Stat. '§ 325F.67; (5) negligence; (6) breach of express and implied warranties; (7) fraud; and (8) misrepresentation. Defendants denied liability and raised numerous defenses. At the time the Settlement was reached, all common-law claims had been dismissed and Plaintiffs’ Motion for Class certification on the remaining claims was pending.

B. Discovery.

This case has been extensively litigated over the past five years. During the course of litigation, the parties conducted thorough discovery, both formally and informally. (Sobol Dec., ¶ 15.)

With respect to informal discovery, Plaintiffs’ counsel (a/k/a “Settlement Class Counsel”) conducted extensive investigation of the claims alleged prior to filing Yarrington’s complaint. In this regard, Plaintiffs’ counsel interviewed potential Class Members, gathered advertisements and marketing material for Estratest, reviewed information about the drug on the internet and in the press, reviewed the drug’s listing in the Physician’s Desk Reference, and ascertained the regulatory status of the drug. (Sobol Dec., ¶ 15.) Plaintiffs’ counsel continued to monitor the regulatory status of the drug and to investigate how it was being marketed and perceived by the medical community throughout the litigation. (Id.) Plaintiffs’ counsel spoke with over 100 women who purchased Estratest. (Id.) Counsel for Plaintiffs also gathered sales data from IMS Health that informed their analysis with respect to the potential damages. (Id.)

Plaintiffs served Solvay with two sets of Requests for Production of Documents, two sets of Interrogatories, and one set of Requests for Admissions. (Sobol Dec., ¶ 16.) Solvay produced more than 224,000 pages of documents to Plaintiffs. (Id.)

Plaintiffs took depositions of Solvay’s corporate representatives, including Greg Tackoor, who testified regarding marketing and distribution of information regarding Estratest; Paul Harding, who testified with respect to issues surrounding personal jurisdiction over Solvay America; and Bruce McMillian and Susan Link, who tes *1060 tified regarding electronic data storage, email, and voicemail. (Sobol Dec., ¶ 16.)

Solvay served each Named Plaintiff with one set of Interrogatories, one set of Requests for Admissions, and two sets of Requests for Production of Documents. (Sobol Dec., ¶ 17.) In response to Solvay’s discovery requests, Plaintiffs produced sensitive and private medical information. (Id.) In addition, Solvay served subpoenas on, or otherwise obtained documents from, Plaintiffs’ physicians, pharmacies, and insurers. (Id.)

Solvay also took the depositions of each Named Plaintiff and her prescribing physician^). (Sobol Dec., ¶ 18.) Solvay deposed Dr. Peter Rost, Plaintiffs’ expert on the issue of pharmaceutical marketing, whose affidavit was attached in support of Plaintiffs’ Motion for Class Certification. (Id.) Plaintiffs retained multiple other experts to analyze damages and to opine regarding Estratest’s regulatory status, and those experts began preparing their reports.

C. Settlement Negotiations.

The parties engaged in two formal but unsuccessful mediation sessions at the Judicial Arbitration and Mediation Service (JAMS) in Los Angeles, California. (Sobol Dec., ¶ 20.) The first session was facilitated by the Honorable Lourdes Baird (Ret.) in December 2007. (Id.) A second mediation session was held on February 19, 2009, facilitated by Justice John K. Trotter (Ret.). (Id.) In anticipation of each mediation session, the parties submitted confidential mediation briefs that focused issues and clarified the relative strengths and weaknesses of their positions. (Id.) At the conclusion of the second mediation session, a settlement demand from Plaintiffs was pending and the parties agreed to continue a dialogue based on the progress made during the meeting. (Id.)

Counsel for Plaintiffs and Solvay stayed in communication with each other by telephone during the months following the second mediation session. (Sobol Dec., ¶ 21.) On June 18, 2009, counsel for the parties participated in an in-person settlement meeting in Atlanta. (Id.) At that meeting, the parties came close to reaching a verbal agreement as to the monetary terms of the settlement, other than attorneys’ fees and costs. (Id.) For several months thereafter, the parties negotiated the terms of the Settlement Agreement. It was not until after all material terms were reached that the parties discussed the amount of attorneys’ fees and costs. The Settlement Agreement was fully executed on August 25,2009. (Id.)

On September 18, 2009, the Court granted preliminary approval of the Settlement and conditionally certified the Settlement Class, consisting of “all natural persons who purchased Estratest in any state of the United States of America other than the State of California between March 8, 1998 and the date notice is first disseminated pursuant to the Notice Plan.” The initial notice plan has since been implemented in accordance with that Order. In compliance with the Preliminary Approval Order and Rule 23(h)(1) of the Federal Rules of Civil Procedure, notice of Settlement Class Counsel’s fee request was included in the Settlement Notice. (Sobol Deck, ¶ 25.)

Pursuant to the initial notice plan, the deadline for objections and exclusions passed on January 2, 2010.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Isbell v. Polaris, Inc.
D. Minnesota, 2023
Kennedy v. ABB Inc.
W.D. Missouri, 2019
Erin Caligiuri v. Symantec Corp.
855 F.3d 860 (Eighth Circuit, 2017)
Pollard v. Remington Arms Co.
320 F.R.D. 198 (W.D. Missouri, 2017)
Huyer v. Wells Fargo & Co.
314 F.R.D. 621 (S.D. Iowa, 2016)
Scheeringa v. McGuire
631 F.3d 913 (Eighth Circuit, 2011)
In Re Unitedhealth Group Inc. Shareholder
631 F.3d 913 (Eighth Circuit, 2011)

Cite This Page — Counsel Stack

Bluebook (online)
697 F. Supp. 2d 1057, 2010 U.S. Dist. LEXIS 24060, 2010 WL 1006518, Counsel Stack Legal Research, https://law.counselstack.com/opinion/yarrington-v-solvay-pharmaceuticals-inc-mnd-2010.